A recent study published in PubMed explores metabolomic responses to oral glucose tolerance tests and hyperinsulinemic-euglycemic clamps in chronic kidney disease (CKD) patients. The findings may provide insights into metabolic dysregulation in CKD, potentially guiding future therapeutic strategies.

A rare case study highlights the relationship between hypertriglyceridemia, chronic kidney disease, and proteinuria in a patient with apolipoprotein C-II amyloidosis. This research contributes to the understanding of the disease's impact on kidney function.

A recent study investigates the impact of acute kidney injury on hospitalization outcomes for patients with chronic kidney disease undergoing cardiac procedures with cardiopulmonary bypass. The findings highlight the significant risks associated with these procedures in this vulnerable patient population.

FDA classifies a prognostic test for assessing chronic kidney disease progression into class II, indicating it will now be subject to special controls. This classification aims to enhance the regulatory framework for devices used in monitoring kidney disease.

R1 Therapeutics has commenced a global Phase 2b trial of AP306 for hyperphosphatemia in patients with chronic kidney disease on dialysis. This first-in-class pan phosphate transporter inhibitor aims to address a significant unmet need in this patient population.